Development of Safe and Non-Self-Immunogenic Mucosal Adjuvant by Recombinant Fusion of Cholera Toxin A1 Subunit with Protein Transduction Domain

Figure 2

Intranasal TCTA1T enhances OVA-specific systemic and mucosal immune responses. (a and b) BALB/c mice were immunized i.n. with 20 μg of OVA alone, plus 10 μg of TCTA1T and TmCTA1T or 2 μg of CT on days 0, 14, and 28. Samples were collected on day 13 or 14 after the last immunization. The levels of OVA-specific IgG1 and IgG2a in sera (a) and IgA in mucosal external secretions (b) were determined by ELISA. (c and d) BALB/c mice were immunized three times at 2-week intervals by i.n. injection with 20 μg of OVA alone, or plus 0.1, 1.0, 10, and 20 μg of TCTA1T, or 2 μg of CT. The levels of OVA-specific IgG in sera (c) and IgA in saliva (d) were determined by ELISA. ND, not detectable. The results are expressed as mean ± SD for the group ( to 6). The data are representative of three separate experiments. The different letters within the same samples are significantly different ().

(a)

(b)

(c)

(d)